NCT03896854View on ClinicalTrials.gov

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 18, 2017

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

CART-19

CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19 cells/kg).

Trial Locations (1)

215000

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

INDUSTRY